Last reviewed · How we verify
GC101 TIL
At a glance
| Generic name | GC101 TIL |
|---|---|
| Sponsor | Shanghai Juncell Therapeutics |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of TIL in Advanced Solid Tumors (CZ) (PHASE1)
- A Study of GC101 TIL in Advanced Melanoma (BZ) (PHASE1, PHASE2)
- A Study of GC101 TIL in Advanced Melanoma (PHASE2)
- A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital) (EARLY_PHASE1)
- A Study of TIL in Advanced Solid Tumors (DFGD) (EARLY_PHASE1)
- Study of GC101 TIL in Brain Glioma (Soochow2) (EARLY_PHASE1)
- A Study of GC101 TIL in Advanced Solid Tumors (TR) (EARLY_PHASE1)
- A Study of GC101 TIL in Advanced Breast Cancer (10hospital) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC101 TIL CI brief — competitive landscape report
- GC101 TIL updates RSS · CI watch RSS
- Shanghai Juncell Therapeutics portfolio CI